BAL
MCID: ACT216
MIFTS: 32

Acute Leukemia of Ambiguous Lineage (BAL)

Categories: Cancer diseases, Immune diseases, Rare diseases

Aliases & Classifications for Acute Leukemia of Ambiguous Lineage

MalaCards integrated aliases for Acute Leukemia of Ambiguous Lineage:

Name: Acute Leukemia of Ambiguous Lineage 52 6
Mixed Phenotype Acute Leukemia 52 71
Acute Biphenotypic Leukemia 52 71
Acute Leukemia of Indeterminate Lineage 52
Acute Leukemia of Undetermined Lineage 52
Undifferentiated Acute Leukemia 52
Acute Undifferentiated Leukemia 71
Mixed Lineage Acute Leukemia 52
Biphenotypic Acute Leukaemia 29
Biphenotypic Acute Leukemia 52
Aml with Lymphoid Markers 52
All with Myeloid Markers 52
Hybrid Acute Leukemia 52
Bal 52

Classifications:



External Ids:

UMLS 71 C0023464 C0280141 C2826025

Summaries for Acute Leukemia of Ambiguous Lineage

MalaCards based summary : Acute Leukemia of Ambiguous Lineage, also known as mixed phenotype acute leukemia, is related to leukemia, acute myeloid and idiopathic acute eosinophilic pneumonia. An important gene associated with Acute Leukemia of Ambiguous Lineage is LOC107303340 (3p25 Von Hippel-Lindau Tumor Suppressor, E3 Ubiquitin Protein Ligase Alu-Mediated Recombination Region). The drugs Cytarabine and Mitoxantrone have been mentioned in the context of this disorder. Affiliated tissues include myeloid, t cells and bone.

Related Diseases for Acute Leukemia of Ambiguous Lineage

Diseases related to Acute Leukemia of Ambiguous Lineage via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 255, show less)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute myeloid 12.0
2 idiopathic acute eosinophilic pneumonia 11.3
3 sarcoidosis 1 10.7
4 lung disease 10.7
5 acute leukemia 10.7
6 idiopathic interstitial pneumonia 10.6
7 pulmonary fibrosis 10.6
8 pulmonary fibrosis, idiopathic 10.6
9 leukemia 10.5
10 dermatitis 10.5
11 pulmonary sarcoidosis 10.5
12 extrinsic allergic alveolitis 10.5
13 mercury poisoning 10.5
14 bronchiolitis 10.5
15 pneumonia 10.5
16 wilson disease 10.4
17 lymphocytic leukemia 10.4
18 bronchiolitis obliterans 10.4
19 interstitial lung disease 10.4
20 cytokine deficiency 10.4
21 leukemia, acute lymphoblastic 10.3
22 myeloid leukemia 10.3
23 bronchitis 10.3
24 allergic hypersensitivity disease 10.3
25 asbestosis 10.3
26 pulmonary tuberculosis 10.3
27 eosinophilic pneumonia 10.3
28 encephalopathy 10.3
29 asbestos intoxication 10.3
30 essential thrombocythemia 10.3
31 invasive aspergillosis 10.2
32 cryptogenic organizing pneumonia 10.2
33 respiratory failure 10.2
34 cystic fibrosis 10.2
35 vascular disease 10.2
36 encephalitis 10.2
37 hypereosinophilic syndrome 10.2
38 graft-versus-host disease 10.2
39 leukemia, acute lymphoblastic 3 10.2
40 precursor t-cell acute lymphoblastic leukemia 10.2
41 asthma 10.2
42 porphyria 10.2
43 bacterial pneumonia 10.2
44 leukemia, chronic myeloid 10.2
45 acute promyelocytic leukemia 10.2
46 lymphoblastic lymphoma 10.2
47 proteasome-associated autoinflammatory syndrome 1 10.1
48 pulmonary disease, chronic obstructive 10.1
49 pneumoconiosis 10.1
50 silicosis 10.1
51 anthracosis 10.1
52 allergic asthma 10.1
53 fibrosis of extraocular muscles, congenital, 1 10.1
54 langerhans cell histiocytosis 10.1
55 hydrops, lactic acidosis, and sideroblastic anemia 10.1
56 pneumocystosis 10.1
57 pulmonary edema 10.1
58 neutropenia 10.1
59 farmer's lung 10.1
60 purpura 10.1
61 histiocytosis 10.1
62 chronic eosinophilic pneumonia 10.1
63 bronchiectasis 10.1
64 heavy metal poisoning 10.1
65 pancytopenia 10.0
66 acute graft versus host disease 10.0
67 chromosomal triplication 10.0
68 tetraploidy 10.0
69 lung cancer 10.0
70 interstitial pneumonitis, desquamative, familial 10.0
71 pulmonary alveolar proteinosis 10.0
72 pneumothorax 10.0
73 nonspecific interstitial pneumonia 10.0
74 syphilis 10.0
75 neuropathy 10.0
76 pulmonary emphysema 10.0
77 alopecia 10.0
78 beryllium disease 10.0
79 granulocytopenia 10.0
80 chronic beryllium disease 10.0
81 leukemia, chronic lymphocytic 10.0
82 down syndrome 10.0
83 myelofibrosis 10.0
84 myeloma, multiple 10.0
85 polycythemia vera 10.0
86 aspergillosis 10.0
87 myelodysplastic syndrome 10.0
88 patau syndrome 10.0
89 visual epilepsy 10.0
90 candidiasis 10.0
91 thrombocytopenia 10.0
92 myeloproliferative neoplasm 10.0
93 hematologic cancer 10.0
94 pyoderma 10.0
95 acute t cell leukemia 10.0
96 monoclonal gammopathy of uncertain significance 10.0
97 childhood leukemia 10.0
98 arthritis 10.0
99 pyoderma gangrenosum 10.0
100 myeloid sarcoma 10.0
101 exophthalmos 10.0
102 b- and t-cell mixed leukemia 10.0
103 47,xyy 10.0
104 splenomegaly 10.0
105 tetrasomy 21 10.0
106 seizure disorder 10.0
107 multiple sclerosis 9.9
108 kaposi sarcoma 9.9
109 proline-negative auxotroph of hamster, complementation of 9.9
110 schistosoma mansoni infection, susceptibility/ 9.9
111 schizophrenia 9.9
112 scleroderma, familial progressive 9.9
113 insulin-like growth factor i 9.9
114 branchiootic syndrome 1 9.9
115 panbronchiolitis, diffuse 9.9
116 allergic rhinitis 9.9
117 mycobacterium tuberculosis 1 9.9
118 pulmonary hypertension 9.9
119 diffuse large b-cell lymphoma 9.9
120 adult respiratory distress syndrome 9.9
121 optic neuritis 9.9
122 hemosiderosis 9.9
123 cutaneous porphyria 9.9
124 schistosomiasis 9.9
125 neuritis 9.9
126 hepatitis 9.9
127 benign mesothelioma 9.9
128 acute porphyria 9.9
129 connective tissue disease 9.9
130 b-cell lymphoma 9.9
131 neuronitis 9.9
132 pulmonary eosinophilia 9.9
133 stomatitis 9.9
134 48,xyyy 9.9
135 mycobacterium avium complex infections 9.9
136 burkitt lymphoma 9.9
137 pelger-huet anomaly 9.8
138 disseminated intravascular coagulation 9.8
139 capillary leak syndrome 9.8
140 lymphadenitis 9.8
141 gastritis 9.8
142 seminoma 9.8
143 conjunctivitis 9.8
144 precursor b lymphoblastic lymphoma/leukemia 9.8
145 chronic monocytic leukemia 9.8
146 chronic graft versus host disease 9.8
147 myelodysplastic syndrome with excess blasts 9.8
148 trisomy 1q 9.8
149 rare tumor 9.8
150 pfeiffer syndrome 9.8
151 gastroesophageal reflux 9.8
152 lymphoma, mucosa-associated lymphoid type 9.8
153 gilles de la tourette syndrome 9.8
154 pemphigus vulgaris, familial 9.8
155 porphyria cutanea tarda 9.8
156 small cell cancer of the lung 9.8
157 ocular motor apraxia 9.8
158 pulmonary alveolar microlithiasis 9.8
159 cd4/cd8 t-cell ratio 9.8
160 lymphangioleiomyomatosis 9.8
161 asthma-related traits 1 9.8
162 anxiety 9.8
163 kala-azar 1 9.8
164 aplastic anemia 9.8
165 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 9.8
166 sarcoidosis 3 9.8
167 lung cancer susceptibility 3 9.8
168 pulmonary fibrosis and/or bone marrow failure, telomere-related, 2 9.8
169 human herpesvirus 8 9.8
170 chorea, childhood-onset, with psychomotor retardation 9.8
171 lower urinary tract obstruction, congenital 9.8
172 deficiency anemia 9.8
173 chlamydia pneumonia 9.8
174 exanthem 9.8
175 intestinal schistosomiasis 9.8
176 small cell carcinoma 9.8
177 lymphoma 9.8
178 pollen allergy 9.8
179 nodal marginal zone lymphoma 9.8
180 sleeping sickness 9.8
181 bacterial infectious disease 9.8
182 japanese encephalitis 9.8
183 brucellosis 9.8
184 chlamydia 9.8
185 heart disease 9.8
186 bronchial disease 9.8
187 nephrotic syndrome 9.8
188 chagas disease 9.8
189 primary biliary cirrhosis 9.8
190 bronchopneumonia 9.8
191 blastomycosis 9.8
192 newborn respiratory distress syndrome 9.8
193 quadriplegia 9.8
194 guillain-barre syndrome 9.8
195 choreatic disease 9.8
196 uveitis 9.8
197 allergic bronchopulmonary aspergillosis 9.8
198 polyneuropathy 9.8
199 bacteriuria 9.8
200 cerebral degeneration 9.8
201 glossitis 9.8
202 pleural disease 9.8
203 histoplasmosis 9.8
204 squamous cell carcinoma 9.8
205 peritoneal mesothelioma 9.8
206 viral hepatitis 9.8
207 opportunistic mycosis 9.8
208 contact dermatitis 9.8
209 acute interstitial pneumonia 9.8
210 adenocarcinoma 9.8
211 chronic granulomatous disease 9.8
212 vaccinia 9.8
213 mixed connective tissue disease 9.8
214 shwartzman phenomenon 9.8
215 rhinitis 9.8
216 poliomyelitis 9.8
217 liver cirrhosis 9.8
218 nutritional deficiency disease 9.8
219 peripheral nervous system disease 9.8
220 hemolytic anemia 9.8
221 congestive heart failure 9.8
222 acquired immunodeficiency syndrome 9.8
223 lung lymphoma 9.8
224 malignant pleural mesothelioma 9.8
225 polycythemia 9.8
226 influenza 9.8
227 mucormycosis 9.8
228 collagen disease 9.8
229 vasculitis 9.8
230 crohn's disease 9.8
231 leishmaniasis 9.8
232 pemphigus 9.8
233 diabetic neuropathy 9.8
234 miliary tuberculosis 9.8
235 acute mountain sickness 9.8
236 congenital hemolytic anemia 9.8
237 exfoliative dermatitis 9.8
238 selenium poisoning 9.8
239 stenotrophomonas maltophilia infection 9.8
240 head injury 9.8
241 tremor 9.8
242 primary pulmonary lymphoma 9.8
243 rapidly involuting congenital hemangioma 9.8
244 virus-associated trichodysplasia spinulosa 9.8
245 fetal lower urinary tract obstruction 9.8
246 argyria 9.8
247 respiratory bronchiolitis-interstitial lung disease syndrome 9.8
248 acute liver failure 9.8
249 obsolete: adult pulmonary langerhans cell histiocytosis 9.8
250 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.8
251 pseudo pelger-huet anomaly 9.8
252 erythrocytosis, familial, 2 9.5 VHL LOC107303340
253 von hippel-lindau syndrome 9.5 VHL LOC107303340
254 renal cell carcinoma, papillary, 1 9.4 VHL LOC107303340
255 renal cell carcinoma, nonpapillary 9.2 VHL LOC107303340

Graphical network of the top 20 diseases related to Acute Leukemia of Ambiguous Lineage:



Diseases related to Acute Leukemia of Ambiguous Lineage

Symptoms & Phenotypes for Acute Leukemia of Ambiguous Lineage

Drugs & Therapeutics for Acute Leukemia of Ambiguous Lineage

Drugs for Acute Leukemia of Ambiguous Lineage (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 238, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Experimental, Investigational Phase 3 147-94-4, 65-46-3 6253
2
Mitoxantrone Approved, Investigational Phase 3 65271-80-9 4212
3
Etoposide Approved Phase 3 33419-42-0 36462
4
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
5
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
6
Ofloxacin Approved Phase 3 82419-36-1 4583
7
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
8
Vindesine Approved, Investigational Phase 3 53643-48-4, 59917-39-4 40839
9
Fludarabine Approved Phase 2, Phase 3 21679-14-1, 75607-67-9 30751
10
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
11
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
12
Ondansetron Approved Phase 3 99614-02-5 4595
13
Dalteparin Approved Phase 3 9005-49-6
14
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
15
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
16
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
17
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 468682 2826718
18
Darbepoetin alfa Approved, Investigational Phase 3 209810-58-2, 11096-26-7
19
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
20
Hydrocortisone acetate Approved, Vet_approved Phase 3 50-03-3
21
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
22
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
24
Mercaptopurine Approved Phase 3 50-44-2 667490
25
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
26
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
27
Daunorubicin Approved Phase 3 20830-81-3 30323
28
Thioguanine Approved Phase 3 154-42-7 2723601
29
Ichthammol Approved Phase 3 8029-68-3
30
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
31
Levoleucovorin Approved, Investigational Phase 3 68538-85-2
32
Pegaspargase Approved, Investigational Phase 3 130167-69-0
33
inotuzumab ozogamicin Approved, Investigational Phase 3 635715-01-4
34
Calcium Approved, Nutraceutical Phase 3 7440-70-2 271
35
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
36 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
37
Cortisone Experimental Phase 3 53-06-5 222786
38
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
39 Antiviral Agents Phase 3
40 Anti-Bacterial Agents Phase 3
41 Antibiotics, Antitubercular Phase 3
42 Topoisomerase Inhibitors Phase 3
43 Etoposide phosphate Phase 3
44
asparaginase Phase 3
45 Calcium, Dietary Phase 3
46 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
47 Anesthetics, Dissociative Phase 3
48 Neurotransmitter Agents Phase 3
49 Analgesics Phase 3
50 Cola Phase 3
51 Antipsychotic Agents Phase 3
52 Central Nervous System Depressants Phase 3
53 Tranquilizing Agents Phase 3
54 Analgesics, Opioid Phase 3
55 Psychotropic Drugs Phase 3
56 Antipruritics Phase 3
57 Anti-Anxiety Agents Phase 3
58 Serotonin Agents Phase 3
59 Serotonin Antagonists Phase 3
60 Liver Extracts Phase 3
61 Antiparasitic Agents Phase 3
62 Antiprotozoal Agents Phase 3
63 Heparin, Low-Molecular-Weight Phase 3
64 Narcotics Phase 3
65 Excitatory Amino Acid Antagonists Phase 3
66 Excitatory Amino Acids Phase 3
67 Anesthetics Phase 3
68 Adjuvants, Anesthesia Phase 3
69 Anesthetics, General Phase 3
70 Anesthetics, Intravenous Phase 3
71 ferric gluconate Phase 3
72 Iron Supplement Phase 3
73 Ferric Compounds Phase 3
74 Liposomal amphotericin B Phase 3
75 Hydrocortisone hemisuccinate Phase 3
76 Hydrocortisone 17-butyrate 21-propionate Phase 3
77 HIV Protease Inhibitors Phase 3
78
protease inhibitors Phase 3
79 Antimitotic Agents Phase 3
80 BB 1101 Phase 3
81 Antineoplastic Agents, Hormonal Phase 3
82
Liposomal doxorubicin Phase 3 31703
83 Trace Elements Phase 3
84 Vitamins Phase 3
85 Micronutrients Phase 3
86 Hydrocortisone-17-butyrate Phase 3
87 Nutrients Phase 3
88 2-Aminopurine Phase 3
89 Hematinics Phase 3
90
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
91
Busulfan Approved, Investigational Phase 1, Phase 2 55-98-1 2478
92
Mycophenolic acid Approved Phase 1, Phase 2 24280-93-1 446541
93
Deferasirox Approved, Investigational Phase 2 201530-41-8 5493381
94
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
95
alemtuzumab Approved, Investigational Phase 2 216503-57-0
96
Voriconazole Approved Phase 2 137234-62-9 71616
97
Allopurinol Approved Phase 1, Phase 2 315-30-0 2094
98
Acyclovir Approved Phase 1, Phase 2 59277-89-3 2022
99
Amifostine Approved, Investigational Phase 1, Phase 2 20537-88-6 2141
100
Mechlorethamine Approved, Investigational Phase 1, Phase 2 51-75-2 4033
101
Ifosfamide Approved Phase 1, Phase 2 3778-73-2 3690
102
Docetaxel Approved, Investigational Phase 1, Phase 2 114977-28-5 148124
103
Phenytoin Approved, Vet_approved Phase 1, Phase 2 57-41-0 1775
104
Idarubicin Approved Phase 2 58957-92-9 42890
105
Everolimus Approved Phase 1, Phase 2 159351-69-6 6442177 70789204
106
Sirolimus Approved, Investigational Phase 1, Phase 2 53123-88-9 5284616 6436030 46835353
107
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
108
rituximab Approved Phase 2 174722-31-7 10201696
109
midostaurin Approved, Investigational Phase 2 120685-11-2 104937 9829523
110
Clofarabine Approved, Investigational Phase 1, Phase 2 123318-82-1 119182
111
Cladribine Approved, Investigational Phase 1, Phase 2 4291-63-8 20279
112
Decitabine Approved, Investigational Phase 1, Phase 2 2353-33-5 451668
113
Sargramostim Approved, Investigational Phase 1, Phase 2 123774-72-1, 83869-56-1
114
Tacrolimus Approved, Investigational Phase 1, Phase 2 104987-11-3 445643 439492 6473866
115
Venetoclax Approved, Investigational Phase 2 1257044-40-8 49846579
116
Azacitidine Approved, Investigational Phase 2 320-67-2 9444
117
Bortezomib Approved, Investigational Phase 2 179324-69-7 387447 93860
118
Vorinostat Approved, Investigational Phase 2 149647-78-9 5311
119
Tyrosine Approved, Investigational, Nutraceutical Phase 2 60-18-4 6057
120 Staurosporine Experimental Phase 2 62996-74-1
121
Treosulfan Investigational Phase 2 299-75-2 9296
122 Imatinib Mesylate Phase 2 220127-57-1 123596
123 Immunoglobulins Phase 1, Phase 2
124 Antibodies Phase 1, Phase 2
125 Antitubercular Agents Phase 1, Phase 2
126 Interleukin-2 Phase 2
127 Anti-HIV Agents Phase 2
128 Mitogens Phase 2
129 Cytochrome P-450 CYP3A Inhibitors Phase 2
130 Steroid Synthesis Inhibitors Phase 2
131 Interferon-alpha Phase 2
132 interferons Phase 2
133 Free Radical Scavengers Phase 1, Phase 2
134 Ophthalmic Solutions Phase 1, Phase 2
135 Antioxidants Phase 1, Phase 2
136 Anti-Asthmatic Agents Phase 1, Phase 2
137
Beclomethasone Phase 1, Phase 2 4419-39-0 20469
138 Flt3 ligand protein Phase 1, Phase 2
139 Radiation-Protective Agents Phase 1, Phase 2
140
Isophosphamide mustard Phase 1, Phase 2 0
141 Epoetin alfa Phase 2 113427-24-0
142 Interleukin-4 Phase 1, Phase 2
143 Sodium Channel Blockers Phase 1, Phase 2
144 polysaccharide-K Phase 1, Phase 2
145 Anticonvulsants Phase 1, Phase 2
146 Diuretics, Potassium Sparing Phase 1, Phase 2
147 Protein Kinase Inhibitors Phase 2
148 Antineoplastic Agents, Immunological Phase 2
149 Thymoglobulin Phase 2
150 Adjuvants, Immunologic Phase 1, Phase 2
151 2-chloro-3'-deoxyadenosine Phase 1, Phase 2
152 Vidarabine Phosphate Phase 2
153 Antibodies, Monoclonal Phase 2
154 Antibodies, Bispecific Phase 2
155 Histone Deacetylase Inhibitors Phase 2
156
Arsenic trioxide Approved, Investigational Phase 1 1327-53-3 518740
157
Topotecan Approved, Investigational Phase 1 119413-54-6, 123948-87-8 60700
158
Pancrelipase Approved, Investigational Phase 1 53608-75-6
159
Vinorelbine Approved, Investigational Phase 1 71486-22-1 60780 44424639
160
Fluorouracil Approved Phase 1 51-21-8 3385
161
carbamide peroxide Approved Phase 1 124-43-6
162
Methoxsalen Approved Phase 1 298-81-7 4114